EMEA-002293-PIP01-17
Key facts
| Active substance |
Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0115/2018
|
| PIP number |
EMEA-002293-PIP01-17
|
| Pharmaceutical form(s) |
Solution for infusion
|
| Condition(s) / indication(s) |
Prevention of oxaliplatin induced peripheral neuropathy
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
PledPharma AB
Tel.: +46 708368702
E-mail: malin.nittve@pledpharma.se |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|